Investors
Get News Alerts!

Overview
Havn Life is focused on the rapidly growing field of psychedelic medicine. We have the opportunity to lead the standardization of psychedelic supply to shift human performance & mental health paradigms.
- DEFINED ROUTE TO NATURAL HEALTH PRODUCTS MARKET.
- PRODUCT FORMULATION OF EFFECTIVE MICRODOSING OF NOVEL PSYCHOACTIVE COMPOUNDS.
- MANAGEMENT TEAM WITH EXTENSIVE CLINICAL & NHP PRODUCT DEVELOPMENT EXPERIENCE.
- DEVELOPING STATE-OF-THE-ART MYCOLOGY LAB FOR PSYCHEDELIC EXTRACTION.
- PARTNERSHIP WITH CANADIAN VETERANS FOR PHASE 1 PRE-CLINICAL RESEARCH.
- RECEIVED FIRST HEALTH CANADA LICENSE IN 2020.

Our Team
Collaboration across disciplines
Creating positive patient experiences and mental health outcomes

Juliana Mollica
Director of Innovation and Quality Assurance
Led projects as the quality assurance and compliance manager for cannabis and pharmaceutical companies to ensure maintenance of GMP requirements, developing QMS for multi-site projects, compliance training programs, and increasing compliance and quality rates.

Sheila Copps
Advisor
The Honourable Sheila Copps was the first woman to ever hold the position of Deputy Prime Minister and served for ten years in the federal cabinet.

Allan Oberman
Advisor
Served as CEO for Concordia International, an international speciality pharmaceutical company with sales in 90 countries and over 200 medicines.

Consultants
Legal Counsel
Cassels
cassels.com
Auditor
De Visser Gray LLP
devissergray.com
Transfer Agent
Odyssey Trust Company
odysseytrust.com

LATEST NEWS
Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing
Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing
Havn Life Sciences provides update on retail strategy and product development
Havn Life Sciences hits major milestone with research partner, Complex Biotech Discovery Ventures
Havn Life Sciences announces increase in Bought Deal Financing to $10 Million
CORPORATE PRESENTATION
